Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31472896 | 0.83 | NQO2 (0.43) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL31472920 | 0.83 | NQO2 (0.43) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL8532411 | 0.83 | KDM4E (0.45) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL26042121 | 0.79 | KMT2A (0.48) | CYP3A4CA9HPGDGAAKDM4E | |
| SCHEMBL4355239 | 0.75 | CYP3A4 (0.47) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL10352684 | 0.75 | CYP3A4 (0.45) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL10415523 | 0.71 | KDM4E (0.53) | CYP3A4ACHEHPGDGAAKDM4E | |
| SCHEMBL145259 | 0.70 | NQO2 (0.44) | HPGDGAAKDM4EPOLBALDH1A1 | |
| SCHEMBL29364806 | 0.70 | NQO2 (0.44) | HPGDGAAKDM4EPOLBALDH1A1 | |
| SCHEMBL725269 | 0.70 | CYP3A4 (0.77) | CYP3A4ACHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025012643-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2025-01-16 | — | — | WO | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2015103355-A1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-2455381-B9 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2455381-B1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-2455381-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | Japan Tobacco, Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | CYP3A4 1081/4885ACHE 3890/4885CA12 3872/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | CYP3A4 4381/4885ACHE 4585/4885CA12 4448/4885 |
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885ACHE 3733/4885CA12 432/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | CYP3A4 3137/4885ACHE 4580/4885CA12 4661/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885ACHE 3733/4885CA12 432/4885 |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | CYP3A4 1081/4885ACHE 3890/4885CA12 3872/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | CYP3A4 1787/4885ACHE 4562/4885CA12 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.